{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087025","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.672595+00:00","generated_at":"2026-06-12T07:32:12.104039+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Cara Therapeutics appoints Helen M. Boudreau, former Novartis CFO, to board","bullets":["Appointed effective August 2, 2023; term expires at 2024 annual meeting.","Boudreau brings 30+ years experience; previously COO of Bill & Melinda Gates Medical Research Institute (2018-2019).","Received initial stock option grant with Black-Scholes value of $350,000, vesting quarterly over three years.","Will receive annual cash retainer of $50k for director service and $10k for audit committee (pro-rated 2023).","Appointed to audit committee; currently serves on boards of Premier Inc., Shattuck Labs, and Rallybio."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087025","json":"https://secwatch.observer/filing/0001104659-23-087025.json","markdown":"https://secwatch.observer/filing/0001104659-23-087025.md","text":"https://secwatch.observer/filing/0001104659-23-087025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/0001104659-23-087025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/tm2322717d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:32:12.104039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a55fa93bef","claim":"Helen M. Boudreau was appointed as member of the Board at Tvardi Therapeutics, Inc..","evidence_excerpt":"On August 2, 2023, upon the recommendation of its nominating and corporate governance committee, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Helen M. Boudreau, M.B.A. to serve as a member of the Board effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/0001104659-23-087025-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}